abmart-banner
Global R&D Pipeline
My Favorite
Hot Targets:
ADGRG1
Back
Total number of drugs
4
Phase II and later clinical stages
0%
Involving companies
2
Main therapeutic areas
Neoplasms
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
DrugDrug Name EnDrug TypeTreatment FieldMechanism of ActionOriginatorDeveloperIndicationHighest Development StageHighest Development Stage (China)Approved Countries/RegionsApproved TimeApproved Time (China)Special ReviewADC TypeADC LinkerADC PayloadADC DARDrug NameAntibody TypeADC Linking SiteOperation
10C7-Duo10C7-DuoAntibody drug conjugate (ADC) ADCNeoplasms Skin and Musculoskeletal Diseasesadhesion G protein-coupled receptor G1 inhibitorsUTHealth HoustonUTHealth HoustonPreclinical10C7-Duo
detail  >
9E3-PBD9E3-PBDAntibody drug conjugate (ADC) ADCNeoplasms Skin and Musculoskeletal Diseasesadhesion G protein-coupled receptor G1 inhibitorsUTHealth HoustonUTHealth HoustonPreclinical9E3-PBD
detail  >
anti-GPR56-ADC(University of Texas Health Science Center At San Antonio)anti-GPR56-ADC(University of Texas Health Science Center At San Antonio)Biological productsNeoplasms Digestive System Disordersadhesion G protein-coupled receptor G1 modulatorsUniversity of Texas Health Science Center At San AntonioUniversity of Texas Health Science Center At San AntonioPreclinicalanti-GPR56-ADC(University of Texas Health Science Center At San Antonio)
detail  >
P7 PeptidesP7 PeptidesPeptidesNervous System Diseasesadhesion G protein-coupled receptor G1 agonistsPreclinicalP7 Peptides
detail  >
Total 4 data
1